T he coexistence of some neuropeptides with classical neurotransmitters is now established. 12 Neuropeptide Y (NPY), a 36 amino acid peptide that has been isolated from porcine brain, 3 -4 is found to be widely distributed throughout the central and peripheral nervous systems. 5 - 6 This peptide is colocalized with norepinephrine in specific neuronal systems. 56 In many cases, the presence of coexistent peptides is believed to influence the release of classical transmitters as neuromodulators. In peripheral tissues such as rat portal vein, it has been observed that NPY has a presynaptic effect and inhibits the stimulation-evoked norepinephrine release. 7 In the central nervous system, we have shown that NPY reduces the stimulation-evoked norepinephrine release in the hypothalamus of Sprague-Dawley rats, and that NPY partially stimulates the presynaptic a 2 -adrenergic receptors in this region. 8 Recent evidence has suggested that NPY might actively participate in the central control of blood pressure because immunohistochemical studies have demonstrated that NPY is located in the nucleus of the solitary tract (NTS) and Cl area in the brainstem. 2 - 910 Fuxe et al n have reported that intracisternal injection of NPY induced hypotension, bradypnea, and electroencephalographic synchronization in the rat. This occurrence may correspond to what is expected to occur after injection of a 2 -agonists such as clonidine into the central nervous system. 11 Agnati et al 12 have observed that NPY increased the number of a 2 -adrenergic binding sites in the membranes of rat medulla oblongata and proposed that NPY might interact with the a 2 -adrenergic receptors.
It is now well known that the a 2 -adrenergic receptors are negatively linked to adenylate cyclase by the inhibitory guanosine triphosphate (GTP)-binding protein (Ni-protein).
13.14 Furthermore, it has been reported that the inactivation of the Ni-protein by In the present study, we investigated the influences of NPY on the electrically evoked pHJnorepinephrine release in rat medulla oblongata and further examined the effects of a 2 -adrenergic agonists and antagonists, as well as the effects of inactivation of the Ni-protein by pertussis toxin, on the modulation of norepinephrine release in this region. Additionally, to test the possibility of abnormal presynaptic regulation of central norepinephrine release in hypertension, we have evaluated whether presynaptic a 2 -adrenergic receptor-mediated and NPY-mediated regulation of norepinephrine release might be altered in the medulla oblongata of spontaneously hypertensive rats.
Methods

Animals
Male Sprague-Dawley (SD) rats weighing 200-250 g (Taconic Farms, Germantown, New York) were used for the fundamental investigation of the effects of NPY in rat medulla oblongata. Male spontaneously hypertensive rats (SHR), 9-10 weeks old (Taconic Farms), were studied compared with agematched male Wistar-Kyoto (WKY) rats (Taconic Farms). The body weight of SHR was 209.6±2.0 (±SEM) g (n=6) and that of WKY rats was 235.3±4.3 g («=6). Systolic blood pressure, which was measured by the tail-cuff method (programmed electrosphygmomanometer, model PE-300, Narco Biosystems Inc., Houston, Texas), was 171.2±1.5 mmHg in SHR (n=6) and 118.8±2.3 mm Hg in WKY rats (n=6). All rats were maintained and housed in a temperature-controlled and humiditycontrolled room. The rats were fed regular pellet food and tap water ad libitum beginning at least 1 week before the experiment.
Drugs
The a 2 -agonists 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline (UK 14, 304) 
Experimental Procedure
The rats were killed by decapitation, and the whole medulla oblongata was rapidly dissected on ice according to the method described previously. 17 The isolated medulla oblongata was sliced at 0. Products, Boston, Massachusetts) for 20 minutes at 37° C. After the slices (5-7 mg) were rinsed with fresh buffer, they were transferred to a superfusion chamber (200 fi\), jacketed with 37° C water, and suspended between two platinum electrodes (25 mm apart, 2.0 mm long). The slices were continuously supervised with Krebs-Ringer bicarbonate buffer at a rate of 0.7 ml/min. The superfusate was collected after 60 minutes of superfusion when basal outflow of tritium had stabilized to a constant level. Samples of superfusate were collected at 7-minute intervals until the end of the experiment (at 130 minutes). For electrical stimulation, trains of unipolar and rectangular pulses (1 Hz, 20 mA, 2 msec duration for 2 minutes) were delivered by using a Grass stimulator (model S4K, Grass Instr. Co., Quincy, Massachusetts). The first period of electrical stimulation (Si) was apphed at 67 minutes, and the second period of electrical stimulation (S2) was applied at 116 minutes after the beginning of the superfusion. At the end of the experiment, the slices were solubilized by sonication for 20 seconds. Radioactivity in the collected samples and solubilized tissues was determined by liquid scintillation spectrometry (Tri-carb Liquid Scintillation Spectrometer, model 3255, Packard Instr. Co., Sterling, Virginia).
The amount of tritium released in each sample was calculated by dividing the total tritium collected in each sample by the total tritium present in the tissue at the time of the sample collection (the tritium released into superfusate after that point plus the tritium remaining in the tissue at the end of the experiment) and was expressed as a percent fractional release. Basal overflow during the two prestimulation periods (bj and bj, respectively) was evaluated from the tritium collected in the two 7-minute samples just before Si and S2. The overflow of tritium evoked by nerve stimulation was calculated by subtracting the basal overflow during the 7-minute prestimulation period from the value in the stimulation period, which included 2 minutes during stimulation plus 5 minutes after stimulation (total 7 minutes). Because more than 85% of tritium released during stimulation represents [ 
In the presence of RX 781,094 The effects of NPY, UK 14,304, and clonidine were evaluated only in S 2 , with Si serving as an internal control. Superfusion with NPY, UK 14,304, and clonidine was initiated 14 minutes before S 2 and maintained until the end of the experiment. The effects of these drugs on the stimulation-evoked [ 3 H]norepinephrine release were determined by comparing the S2/S1 ratios obtained in control slices with the values in slices treated with the tested drug in S 2 . To examine the effects of blockade of a 2 -adrenergic receptors, RX 781,094 (lxlO" 8 M) was added to the superfusion medium 28 minutes before S, and maintained until the end of the experiment. To inactivate the Ni-protein, the slices of medulla oblongata were preincubated for 1 hour at 37° C in an atmosphere of 95% O 2 and 5% CO 2 in a mixture of 1,380 fil Krebs-Ringer bicarbonate buffer and 120 pi 0.01 M sodium phosphate buffer that contained 0.05 M sodium chloride and 12 jig pertussis toxin (concentration, 8 /xg/ml). In control experiments, the slices were incubated in the same buffer mixture without pertussis toxin. Subsequently, the slices were washed three times with fresh buffer and incubated in the presence of 0.1 pM In the second series of experiments, the effects of UK 14,304 and NPY on the stimulation-evoked 3 H]norepinephrine release were studied in the medulla oblongata of SHR compared with WKY rats.
Statistics
Data are presented as mean±SEM. Differences between the means of the drug treatment and their corresponding controls were tested by one-way analysis of variance (ANOVA). To examine the differences between SHR and WKY rats, two-way ANOVA was used. Ap value less than 0.05 was accepted as the level of significance. Table 1 show that inhibitory potency of NPY was significantly attenuated in the presence of RX 781,094.
Results
Effects of Neuropeptide Y Alone and in Combination
Effects of Pertussis Toxin on the Inhibition of Norepinephrine Release by UK 14,304 and Neuropeptide Y in Medulla Oblongata of Sprague-Dawley Rats
The stimulation-induced fractional release of [ 3 H]norepinephrine was not altered by the treatment of pertussis toxin ( Table 2 ). The inhibitory action of UK 14,304 and NPY on [ 3 H]norepinephrine release, however, was significantly reduced in slices pretreated with pertussis toxin (Table 2) .
Effects of UK 14,304 and Neuropeptide Y on Norepinephrine Release in Medulla Oblongata of Spontaneously Hypertensive Rats and Wistar-Kyoto Rats
As shown in Discussion NPY coexists with norepinephrine and epinephrine in a specific neuronal system, involving the NTS and the Cl area in the brainstem.
-
10 This peptide is believed to be coreleased with catecholamines by sympathetic activation 19 and to have a modulatory action on catecholamine release. We have, therefore, investigated the effects of NPY on norepinephrine release and its interactions with a 2 -adrenergic receptors in rat medulla oblongata. The results of the present study demonstrate that NPY inhibits the stimulation-evoked fHJnorepinephrine release from slices of rat medulla oblongata in a dose-dependent manner. This occurrence confirms our previous observation that NPY inhibited the stimulationevoked norepinephrine release in rat hypothalamus. 8 The a 2 -adrenergic receptor agonists UK 14,304 and clonidine also strongly inhibit the stimulation-evoked It is well known that a 2 -adrenergic receptors are linked to the Ni-protein. 13 
>
14 Pertussis toxin inactivates the Ni-protein by adenosine diphosphateribosylation of the a-subunit and has been used to determine the involvement of the Ni-protein in the receptor-mediated inhibition of adenylate cyclase or in the overall cellular responses elicited by activation of the receptors. 1516 The present study shows that UK 14,304-induced and NPY-induced decrease in 22 have reported that NPY increased the number of a 2 -adrenergic receptor binding sites in membrane preparations of WKY, whereas NPY failed to increase the binding sites in membrane preparations of SHR, and they suggested that the possible interactions between NPY and a 2 -adrenergic receptors might be disturbed in SHR. Further studies are required to determine the interactions of NPY with a 2 -adrenergic receptors and their role in the regulation of norepinephrine release in the central nervous system of SHR.
In contrast to our functional results, an increased NPY binding site has been observed in the hippocampus and cerebral cortex of SHR. 23 Maccarrone and Jarrott 24 have investigated regional concentrations of NPY immunoreactivity in the brain of SHR, and found that the NPY concentration in SHR was decreased in cortex, cervical and thoracic spinal cord, midbrain, and medulla oblongata-pons, whereas it was increased in striatum compared with WKY rats. Thus, it seems likely that there may be some regional differences in NPY level and its physiological functions in the brain of SHR. Furthermore, less sensitivity to NPY in medulla oblongata of SHR might not be due to down-regulation of the NPY receptors in this region.
Tseng et al 25 have reported that microinjection of NPY into the NTS causes a dose-dependent reduction of blood pressure and heart rate. Edvinsson et al 26 have proposed that the possible end results of the NPY effect might be an improvement in "norepinephrine economy" at the synaptic junction, which is reflected in reduced norepinephrine demand and a suppression of norepinephrine release after nerve stimulation, and they suggested that NPY might cooperate with norepinephrine in sympathetic neurons. Therefore, the impaired action of NPY in medulla oblongata of SHR might indicate the abnormal interactions of the peptide with central sympathetic neurons, which would have a role in the pathogenesis of hypertension.
The present study shows that NPY inhibits stimulation-evoked norepinephrine release in rat medulla oblongata, and that a part of the mechanisms may be explained by the interactions with presynaptic a 2 -adrenergic receptors and pertussis toxin-sensitive GTP-binding proteins. The impaired modulation of norepinephrine release by NPY in medulla oblongata of SHR might suggest that NPY is involved in the regulation of central sympathetic nervous activity in hypertension.
